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Abstract 
Major Depressive Disorder (MDD) is common among cancer patients, with 
prevalence rates up to four-times higher than the general population. Depression 
confers worse outcomes, including non-adherence to treatment and increased 
mortality in the oncology setting. Advances in the understanding of neurobiological 
underpinnings of depression have revealed shared biobehavioral mechanisms may 
contribute to cancer progression. Moreover, psychosocial stressors in cancer promote: 
(1) inflammation and oxidative/nitrosative stress; (2) a decreased 
immunosurveillance; and (3) a dysfunctional activation of the autonomic nervous 
system and of the hypothalamic-pituitary-adrenal axis. Consequently, the prompt 
recognition of depression among patients with cancer who may benefit of treatment 
strategies targeting depressive symptoms, cognitive dysfunction, fatigue and sleep 
disturbances, is a public health priority. Moreover, behavioral strategies aiming at 
reducing psychological distress and depressive symptoms, including addressing 
unhealthy diet and life-style choices, as well as physical inactivity and sleep 
dysfunction, may represent important strategies not only to treat depression, but also 
to improve wider cancer-related outcomes. Herein, we provide a comprehensive 
review of the intertwined biobehavioural pathways linking depression to cancer 
progression. In addition, the clinical implications of these findings are critically 
reviewed.    
 
Keywords: major depressive disorder, cancer, inflammation, HPA axis, stress, 
psychiatry 
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Highlights:  
 
• Depression is highly prevalent among individuals with cancer 
• Co-morbid depression may lead to a worse prognosis among cancer patients 
• Preclinical and clinical evidence instantiate the role of inflammation and 
oxidative and nitrosative stress in the pathophysiology both of cancer and 
depression 
• Psychosocial stressors in cancer promote inflammation, a dysregulated 
activation of the hypothalamic-pituitary-adrenal axis and reduced 
immunosurveillance 
•  Behavioral strategies may target biological mechanisms relevant to tumor 
progression and depressive clinical manifestations 
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Introduction 
Major Depressive Disorder (MDD) is more common among individuals affected by 
cancer as compared to the general population. While the average rate of MDD is 3.3% 
in the general population, the prevalence of MDD among individuals with cancer is 
approximately 12.5%, which is up to four-times the rate reported in population-based 
samples 1. Evidence indicates that co-morbid depression may be associated with a 
worse prognosis and increased mortality rate in cancer populations 2. In fact, 
depression is an independent predictor of more frequent and longer hospitalizations, 
diminished quality of life and decreased compliance to treatments 3. Meta-analytic 
evidence indicates that depression triples the risk for non-adherence to medications in 
women with breast cancer 4. Moreover, demotivation may promote maladaptive 
depressive coping styles with a detrimental effect on survival 5 as well as potentially 
increase suicidal risk 6. Notwithstanding depression is under-recognized in cancer 
population, limited evidence provides support for the routine screening of distress in 
cancer populations 7. Importantly, the treatment of depression has been associated 
with increased survival in women with metastatic cancer 8. Furthermore, interventions 
aiming at improving depression management, education and behavioral activation 
(i.e. emphasizing pleasant event scheduling and overcoming avoidance behaviors), 
along with the use of antidepressant treatments when appropriate, have been 
recognized as effective in reducing depressive burden in individuals with cancer 9.  
Notwithstanding the burgeoning and stressful potential associated with a diagnosis of 
cancer, the large prevalence of depression among individuals with cancer is likely to 
not be entirely explained by the effects of psychological distress. In recent years, 
advances in the neurobiology of depression and in the physiopathology of cancer have 
led to the identification of some shared bio-behavioral mechanisms 10-14. This field 
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has witnessed an ever increasing accumulation of emerging findings, which deserve a 
critical review.  
Therefore, this comprehensive narrative review aims to: 1) explore epidemiological 
links between depression and cancer progression; 2) summarize biological 
mechanisms relevant for the development and recurrence of depressive episodes as 
well as for cancer progression, with potential mutual reciprocal interactions; and 3) 
describe behavioral interventions that may target mechanistic pathways relevant to 
both depression and cancer progression.   
Search Strategy 
A comprehensive search for peer-reviewed articles published in English was 
performed in the PubMed/Medline database including the following search terms: 
“Major Depressive Disorder”, “cancer”, “tumor”, “inflammation”, “oxidative and 
nitrosative stress”, “HPA axis”, “diet”, “microbiota”, “physical exercise”, “sleep 
dysfunction” up until February 15th, 2016. Bibliographies from selected articles were 
reviewed to identify additional original reports aligned with our objectives. 
Epidemiological links between depression and cancer  
Most studies report that the prevalence of depression in oncological populations range 
from 15% to 30%, with variations attributable to different screening tools and 
diagnostic criteria across studies 15. These heterogeneous results are in part 
explainable by the fact that only a limited number of studies have assessed the 
prevalence of depression in cancer samples used a structured diagnostic interview 
according to criteria established in the Diagnostic and Statistical Manual of Mental 
Disorders (DSM) or the International Classification of Diseases (ICD). On the 
contrary, it is noteworthy that self-rated reports of depression or the detection of 
  
 6
depressive symptoms by clinicians do not substantiate a reliable diagnosis of MDD. 
In keeping with this view, it is not surprising that the prevalence of individuals 
meeting a diagnosis of MDD according to a structured clinical interview is relatively 
lower compared to the prevalence of depressive symptoms among individuals with 
cancer 16. Meta-analytic evidence of 24 studies involving 4007 subjects from 
palliative-care settings documented a prevalence of MDD as defined according to the 
DSM-IV of 16.5% (95% CI 13.1–20.3), while the prevalence of all types of 
depression was 20.7% (12.9– 29.8) and that of minor depression of 9.6% (3.6–18.1) 
17
. A recent meta-analysis examining the role of depression as a putative risk of 
cancer have been recently conducted 18. This meta-analysis of nine observational 
studies demonstrated that a DSM or ICD diagnosis of depression was not 
conclusively associated with cancer risk. In addition, there was a lack of well-
designed prospective cohort studies examining this association 18.  
Depressive symptoms typically develop during the first year after cancer diagnosis 
and usually decline as a result of adaptive adjustments to psychological stress related 
to the diagnosis 19. For instance, in an epidemiological survey exploring the 
prevalence of depressive symptoms among subjects of five biennial waves of the 
Health and Retirement Study, involving 8,387 individuals aged 51-61, subjects 
diagnosed with cancer had the highest hazard ratio of depressive symptoms within 2 
years following initial diagnosis (HR 3.55; 95%, CI, 2.79-4.52), when compared to 
individuals diagnosed with diabetes, hypertension, heart disease, arthritis, chronic 
lung disease or stroke 20. The chances of developing a new depressive episode 
following a diagnosis of cancer may be elevated in certain vulnerable groups (e.g., 
those patients with a previous history of depressive episodes), as suggested by an 
observational study exploring the relationship between acute stress disorder and 
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subsequent depressive symptoms after a diagnosis of head/neck/lung cancer 21. In this 
study up to 29% of individuals met the criteria for MDD within the first month after 
the diagnosis, of whom nearly one-third had a positive history for previous depressive 
episodes 21.  
There is also some accumulating evidence indicating that affective and somatic 
depressive symptoms may occur prior to the establishment of a cancer diagnosis 22, 23. 
For instance, a previous study among people with a new diagnosis of pancreatic 
cancer, found that affective symptoms were evident several months before the cancer 
diagnosis in addition to somatic symptoms including fatigue, anorexia, and insomnia 
24
. Somatic symptoms are extremely common among populations with different types 
of cancer and may potentially be an expression of both depression and/ or the 
underlying neoplasm 25. However, in spite of the fact that fatigue and weight loss/gain 
are more frequently reported by women with ovarian cancer during advanced (stages 
III–IV) versus early (stages I–II) stages, the onset of these symptoms may begin up to 
2–7 months prior to diagnosis, suggesting that these manifestations may result from 
shared mechanisms that also drive tumorigenesis 26. Furthermore, in women awaiting 
surgery for suspected ovarian cancer, depressive symptoms have been reported more 
frequently in those receiving a subsequent diagnosis of cancer compared to those with 
tumors of low malignant potential 27. Similarly, depressive symptoms have been 
documented in up to approximately 30% of women before the diagnosis of breast 
cancer 28. However, other studies have provided contrasting results and have not 
reported a significant difference in depressive symptom severity in women with a 
subsequent diagnosis of breast cancer as compared to women with a benign breast 
disease 29. Lastly, it should be noted that cancer treatment may also contribute to the 
development of depressive symptoms. Immune-inflammatory and O&NS alterations 
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following chemotherapy may be partially responsible for the worsening and/or the 
initiation of somatic and affective symptoms of depression, including fatigue, sleep 
dysfunction and cognitive complaints 30. 
The role of stress and inflammation 
Tumorigenesis and cancer progression are characterized by the acquisition of six 
biological attributes, representing the “hallmarks of cancer” namely (1) resisting cell 
death; (2) sustaining proliferative signaling; (3) evading growth suppressors; (4) 
inducing angiogenesis (5) resisting cell death; and (6) activating invasion and 
metastasis 31. Continued oxidative stress can propitiate chronic inflammation, which 
may influence cancer progression. Hence, oxidative stress can activate transcription 
factors and lead to the expression of over 500 different genes, including those related 
to growth factors, pro-inflammatory cytokines, chemokines, cell-cycle regulatory 
molecules, and anti-inflammatory molecules, suggesting that oxidative stress, chronic 
inflammation, and cancer are closely intertwined 32. 
Host factors, including cell-mediated immunity, are involved in surveillance and 
destruction of tumor cells, especially in early disease stages. Stress-induced processes 
can directly modulate these tumor hallmarks and a large body of preclinical and 
clinical evidence supports the role of inflammation as an essential factor for tumor 
growth and progression 1. Pro-inflammatory cytokines are produced by tumor and 
stromal cells, as well as by tumor-associated macrophages and infiltrating T-cells, and 
play an important role in tumor angiogenesis, metastatic spread, and possibly 
resistance to therapy 22, 33. In addition, stress-related effects on angiogenesis may be 
regulated by neural control mechanisms. In particular, stressors promote angiogenesis 
via enhanced adrenergic transmission, which stimulate the production of cytokines 
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(e.g., IL 6, IL-8, TNF-α) and vascular endothelial growth factor (VEGF) by the 
activation of cognate beta-adrenergic receptors on tumor and stromal cells 34. 
Furthermore, stress-induced activation of the sympathetic nervous system promotes 
metastatic invasion via an increase in the expression of enzymes endowed with the 
ability of destroying the cellular matrix surrounding the tumor, e.g. matrix 
metalloproteinases (MMP) 2 and MMP-9, which are produced by both tumor cells 
and macrophages in the tumor microenvironment and may be regulated by stress-
triggered factors 35. On the contrary, the activation of the parasympathetic nervous 
system appears to down-regulate the immune response and dampen the production of 
pro-inflammatory cytokines, through cholinergic-mediated decrease in the expression 
of nuclear factor kappa B (NF-κB), an effect referred to as the “cholinergic anti-
inflammatory pathway” 36.  
The production of cytokines in the periphery leads to an amplification of the pro-
inflammatory response at the central nervous system (CNS) via an increase in the 
permeability of the blood-brain barrier (BBB) on circumventricular organs and in the 
choroid plexus, or via afferent vagal fibers innervating the nucleus of the solitary tract 
37
. In addition, growing evidence indicates that perivascular monocytes may infiltrate 
the brain, promoting the spread of inflammatory stimuli to microglia and astrocytes, 
which in turn become the main source of immune-inflammatory mediators within the 
brain 38. A large body of preclinical and clinical data indicates that an increase in pro-
inflammatory cytokines are associated with the so-called “sickness syndrome”, whose 
manifestations include anhedonia, irritability, psychomotor retardation, fatigue, 
anorexia, insomnia, and increased pain sensitivity 39. Those symptoms overlap to 
some extent with the clinical manifestations of depression and are partly responsive to 
antidepressant treatments. Thus, the immune cross-talk between the central nervous 
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system (CSM) and the periphery is thought to be largely responsible for the 
development of somatic and affective symptoms of depression under pro-
inflammatory conditions, while also possibly contributing to carcinogenesis 40.  
Inflammatory aberrations associated with depression 
Literature supporting the role of inflammation in depression is extensive. Increased 
expression of innate immune mediators, including cytokines and acute phase 
reactants, chemokines and soluble receptor molecules are among the most replicated 
findings not only in peripheral blood but in the cerebrospinal fluid (CSF) or in post-
mortem brain samples of suicide victims 41. For instance, some meta-analyses have 
documented higher peripheral levels of pro-inflammatory cytokines namely IL-6, IL-
8, IL-1β, TNF-α, soluble IL-2 receptor (sIL-2R) and C-reactive protein (CRP) in 
individuals with MDD when compared to healthy controls 42, 43. Conversely, in 
longitudinal population studies, higher CRP levels have been demonstrated to 
predispose individuals in developing subsequent depressive symptoms, thus 
supporting that the notion that the activation of the immune system may contribute to 
the patho-etiology of depression 44. Further support to this idea derives from evidence 
that the administration of interferon alpha (IFN)-α to patients with cancer is 
associated with the development of depressive symptoms, that only partially respond 
to conventional antidepressant treatments 45. Polymorphisms in inflammatory 
cytokine genes, including those encoding for IL-1β, TNF-α and CRP, have also been 
related to antidepressant treatment response 46. 
In addition to evidence instantiating the role of innate immunity in the 
pathophysiology of depression, other lines of research focused on alterations in 
adaptive cellular immunity 47. In fact, increased levels of pro-inflammatory cytokines 
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and reduced signaling of anti-inflammatory mediators, such as IL-10 and 
transforming growth factor beta (TGF-β), may direct the differentiation of T naïve 
cells towards the T helper 1 (Th1)/Th17 phenotype instead of T regulatory (T reg) 
cells, further promoting the production of pro-inflammatory mediators (e.g., IFN, IL-
2) in a vicious circle 48, 49. Pro-inflammatory cytokines stimulate the activation of the 
enzyme indoleamine 2-3 dioxygenase (IDO), which converts tryptophan into 
kynurenine (KYN), leading to serotonin deprivation 50. In microglial cells, KYN may 
be further converted into quinolinic acid (QUIN), a powerful N-methyl-D-aspartate 
(NMDA) agonist and stimulator of glutamate release. QUIN and other tryptophan 
catabolites induce the further production of pro-inflammatory cytokines and 
potentiate oxidative and nitrosative stress provoking lipid peroxidation, mitochondrial 
dysfunction and DNA damage 51. In this context, it is noteworthy to highlight that 
recent research also pointed to a role of IDO in the control of inflammation and in 
peripheral immune-tolerance in cancer patients 52. In fact, IDO activation can be 
triggered by innate responses during tumorigenesis, and also by T cell activation, thus 
representing a potential target for immunotherapy.  
Finally, cascades associated with the activation of the aforementioned pathways 
appear to lead to excitotoxic neural damage,  a reduced expression of brain derived 
neurotrophic factor (BDNF) and consequently to a disruption of mechanisms 
subserving neural plasticity 53, 54. In addition, oxidative stress may reduce the activity 
of 5,6,7,8-tetrahydrobiopterin (BH4), which is a co-factor for several aromatic amino 
acid monooxygenases and is rate-limiting for the biosynthesis of the neurotransmitter 
serotonin and the catecholamines dopamine, epinephrine and norepinephrine 55. Thus, 
the reduced biosynthesis of catecholamines may also be related to disturbed 
adrenergic neurotransmitter pathways under chronic low-grade inflammatory states. 
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During the last decade, the hypothesis of a pro-inflammatory imbalance implicated in 
the pathophysiology of depression has gained momentum, and provided the rationale 
for testing putative antidepressant properties of several non-steroidal anti-
inflammatory drugs and cytokine inhibitors 56. Of note, anti-inflammatory treatments 
may represent useful treatment options in particular for a subset of individuals with 
MDD exhibiting low-grade chronic activation of pro-inflammatory pathways. For 
instance, treatment with the TNF antagonist infliximab was effective in reducing 
depressive symptoms in individuals with treatment-resistant MDD showing baseline 
CRP levels > 3 mg/dl 57. In this study, treatment response was associated with 
transcriptional signatures related to glucose and lipid metabolism 58. Maladaptive 
habits, including unhealthy diet and smoking, as well as environmental factors, 
including childhood abuse, have been consistently associated with pro-inflammatory 
activation 59. For instance, individuals with a history of childhood abuse exhibit 
higher plasma CRP, IL-6 and TNF-α levels during adulthood in comparison to 
healthy controls 60 and are exposed to greater risk of chronic diseases in adulthood 
including cancer, depression, cardiovascular disease and metabolic syndrome 61. 
Consequently, the characterization of a subset of MDD subjects more marked 
disruption of pro-inflammatory pathways has emerged as a relevant priority in this 
field of research.  
Immune activation and alterations in stress response in depression associated with 
cancer 
The presence of comorbid depression has been demonstrated to have a negative 
prognostic impact across different cancer populations. For instance, depression has 
been associated with shorter survival in patients with renal carcinoma 62. Of note, a 
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subgroup analysis revealed that increased gene expression related to inflammatory 
pathways and oxidative stress as well as greater activity of the nuclear transcriptional 
factor NF-kB in circulating leucocytes, were positively associated with depressive 
symptoms’ severity 62. In keeping with this view, elevated concentrations of cytokines 
(e.g., IL-6 and TNF-α) have been associated with later cancer stages, poor 
differentiation and tumor size/volume across a variety of malignancies. Therefore, the 
detrimental prognostic impact of depression in comorbidity with cancer may be at 
least in part mediated by  the activation inflammatory cascades 22. For example, 
increased plasma levels of IL-6 were observed in association with depressive 
symptoms in individuals with advanced ovarian cancer as compared to subjects with 
tumors of low-grade malignant potential 27. Similarly, IL-6 levels have been 
associated with depressive symptoms in individuals with cancer 10. In addition, 
increased plasma levels of the IL-1 receptor antagonist and soluble TNF receptor 2 
(sTNFR2) correlated with fatigue in breast cancer survivors up to 5 years after the 
diagnosis 63. Lastly, the blockade of cytokines’ signaling has been associated with 
reductions in depressive symptoms and better quality of life in patients with advanced 
cancer 64.  
Unsurprisingly, abnormalities in the stress responses appear to be closely linked to the 
immune activation. For instance, pro-inflammatory activation is highly associated 
with hypothalamic–pituitary–adrenal (HPA) axis dysfunction, notably higher evening 
cortisol levels 27. A dysregulated pattern of cortisol secretion has been consistently 
associated with depression and fatigue in cancer patients 65. Elevated nocturnal 
cortisol levels and a flattened diurnal cortisol slope have been observed in individuals 
with breast, ovarian, cervical cancer and lymphoma, and may predict poor survival 66. 
These abnormalities in cortisol secretion appear to stimulate the growth and survival 
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of cancer cells, leading cancer treatment resistance and inhibiting apoptosis of tumor 
cells 67. Moreover, glucocorticoids negatively influence DNA repair and modulate 
genetic transcriptional activities 68. 
The treatment of cancer may in part mitigate pro-inflammatory aberrations and the 
dysfunctional activation of the HPA axis. For instance, surgical treatment followed by 
chemotherapy in high-risk ovarian cancer patients was found to be effective in 
reducing IL-6 levels and nocturnal cortisol and in improving neurovegetative 
symptoms of depression, fatigue and quality of life 69. However, other lines of 
evidence indicate that cancer treatments may induce per se inflammatory pathways 
relevant to the development of depressive symptoms. For instance, chemotherapy has 
been associated with an increase in the activity of NF-kB as well as an increase in 
levels of IL-6 and sTNFR2 in parallel to increases in depressive symptoms in women 
with breast cancer 70.  
Further support to the involvement of inflammation in the development of cancer-
associated depression derives from the evidence that subjects with cancer receiving 
IFN treatment have a greater likelihood to exhibit depressive symptoms. Up to 50% 
of individuals with melanoma treated with IFN develop a variety of neurobehavioural 
symptoms including psychomotor retardation, anorexia, insomnia, and fatigue 71. The 
presence of depressive symptoms prior to IFN treatment has been recognized as one 
of the most robust predictors of depression, and is may be an exclusion criterion for 
IFN therapy because of the substantial risk of depression 72.  
Use of antidepressants and cancer 
The use of antidepressant treatment is associated with reductions in depressive 
symptoms across cancer samples, as documented by several randomized controlled 
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trials (RCTs) utilizing mianserin 73, serotonin reuptake inhibitors (SSRIs; e.g. 
fluoxetine and paroxetine) 71 as well as tricyclic antidepressants (TCAs; e.g. 
amitriptyline and desipramine) 74. In addition, some antidepressants (e.g. mirtazapine) 
may also alleviate chemotherapy-induced nausea and cancer-related cachexia-
anorexia 75, 76. Prophylactic treatment with paroxetine was effective in reducing 
depressive symptoms after IFN treatment 71. Therefore, the assessment of depressive 
symptoms among individuals with cancer prior to treatment initiation may aid in the 
identification of vulnerable subjects for whom prophylactic antidepressant treatment 
may be indicated. However, since only up to 30% of individuals with MDD achieve 
symptomatic remission following a trial with a first-line antidepressant treatment 77, 
the identification of novel alternative or complementary treatment strategies is a 
priority for improving outcomes of depressed individuals suffering from cancer.  
On the other hand, several clinical and experimental studies have suggested a link 
between antidepressant use and cancer 78. Epidemiological studies on the effects  of  
antidepressants on cancer prognosis suggest that the long-term use of TCAs and 
SSRIs may increase the risk of breast 79, 80 and ovarian cancer 81, whereas the use of 
TCAs may increase risk of prostate cancer and non-Hodgkin’s lymphoma 82. 
However, several further studies did not find a significant association between 
antidepressant treatment and risk towards breast and ovarian cancers 83, and non-
Hodgkin’s lymphoma 84. Moreover, regular use of SSRIs may reduce risk of 
colorectal 85 and lung 86 cancers. 
 Whereas epidemiological studies concentrated on the association between 
antidepressant drugs and cancer incidence, animal models of cancer have been used to 
delineate the effects of antidepressant drugs on cancer progression 87. Thus, fluoxetine 
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administration after B16F10 melanoma cells injection dramatically inhibited solid 
tumor growth 88, whereas chronic pretreatment with fluoxetine or desipramine before 
melanoma cells inoculation dramatically promoted metastasis formation and 
increased mortality rate in highly active young male and female animals by impairing 
the efficiency of anti-tumor immunity and enhancing the implantation efficiency of 
melanoma cells 89, 90. Kubera et al. (2011) reported a decreased production of Th1 
cytokines and increased IL-10/IFN-gamma ratio in high-active C57BL/6J mice 
pretreated with desipramine (males) and fluoxetine (females) before injection of 
melanoma cells (decreasing antitumor immunity). The mechanism of metastatic 
promotion by the pretreatment with antidepressant drugs before the inoculation of 
tumor cells deserve further examination, and may have relevant clinical implications. 
For example, cancer patients taking antidepressants before surgical manipulation may 
show an increased risk of cancer cell dissemination during surgery 90, although further 
studies are required to fully appreciate the benefits and harms of antidepressant use in 
individuals with malignancies. 
Effects of oxidative and nitrosative stress (O&NS) 
 Chronic inflammation characterised by elevated levels of pro-inflammatory 
cytokines leads to activation of inducible nitric oxide synthase (iNOS) and increased 
activity of several transcription factors, such as NF-κB (nuclear factor κB), AP-1 
(activator protein 1) and STAT3 (signal transducer and activator of transcription 3) 
leading in turn to upregulated activity of NADPH oxidase (NOX) and mitochondrial 
oxidoreductases 91. The activation of these enzymes and transcription factors lead to 
the chronic activation of a wide range of inflammatory pathways subsequent to the 
up-regulation of COX-2 (cyclo-oxygenase-2), and the development of a state of 
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chronic O&NS characterised by excessive production of reactive oxygen species 
(ROS), such as the superoxide anion, and reactive nitrogen species (RNS), such as 
nitric oxide (NO), which are known to play a major role in the pathogenesis and 
pathophysiology of major depression and inflammatory cancers 92. 
There is now evidence that depression is accompanied by an increase in O&NS as 
indicated by an increase in lipid peroxidation, oxidative and nitrosative damage to 
DNA, nitrosative damage to proteins, hypernitrosylation, autoimmune responses to 
oxidatively and nitrosatively modified epitopes (neoepitopes, including 
malondialdehyde (MDA), oxidized LDL and NO-adducts 93, 94. These activated 
O&NS pathways are partly related to lowered levels of key antioxidants including 
lowered levels of coenzyme Q10, zinc, vitamin E, glutathione, HDL-cholesterol, 
albumin, etc. 93. Both the activated O&NS pathways and lowered levels of key 
antioxidants may be associated with different symptom profiles, the specific 
neurotransmitter pathophysiology of depression and staging of depression including 
chronicity of depression (e.g. increased autoimmune responses to neoepitopes) and 
treatment resistance (e.g. lowered coenzyme Q10 and zinc) 93. In addition, increased 
ROS, RNS, lipid peroxidation, and lowered levels of antioxidants such as zinc and 
coenzyme Q10 aggravate existing inflammatory responses, and may cause 
autoimmune responses leading to more inflammation and cause chronic inflammatory 
responses 93. Another dimension of pathology involves the consequences of 
hypernitrosylation, that is increased nitrosylation of cysteine groups in selected 
proteins by nitric oxide (NO) 93. There is some evidence that abnormal levels of this 
post transcriptional modification may underpin the degenerative processes including 
neurodegeneration, abnormal hippocampal long-term potentiation, impaired 
synaptogenesis, neuronal survival 93, 94.  
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An abundant amount of evidence has illustrated that activated O&NS pathways play a 
role in the pathophysiology and maybe the onset of specific cancers. Firstly, elevated 
levels of ROS and RNS, in an environment of compromised cellular antioxidant 
defences, may damage DNA, lipids and proteins and may lead to DNA mutations 92. 
Such macromolecular damage leads to compromised protein functions, mitochondrial 
impairment, compromised cell membrane integrity, genetic instability and the 
formation of damage associated molecular patterns whose engagement with pattern 
recognition receptors can create a cascade of self-amplifying immune-inflammatory 
and O&NS pathology as detected in different cancers 95. ROS signalling plays a major 
role in the regulation of metabolism, cell fate, tumour cell proliferation, angiogenesis, 
and metastasis. A second dimension of pathology involves the consequences of 
abnormal nitrosylation of cysteine groups in selected proteins by NO 96. S–
nitrosylation is now recognised as a major vehicle enabling the regulation of redox 
based protein signal transduction by NO in a cellular environment 97, 98 and its 
dysregulation can produce a plethora of pathogenic consequences in several disease 
areas, including cancer 99. A state of hypernitrosylation caused by excessive levels of 
NO and dysregulated S-nitrosylation are implicated in the genesis and progression of 
cancer as well as treatment resistance 100. For example, tumour growth is regulated by 
S-nitrosylation of Ras and the epidermal growth factor receptor 101. Cellular migration 
and cancer invasiveness may be enhanced by nitrosylation on the integrin alpha chain 
and nitrosylation of c-Src 102 in prostate and breast cancers. Dysregulated S-
nitrosylation also seems to explain, at least in part, the Janus faced role of NO in 
cancer whereby the molecule exerts pro-tumorigenic or anti-tumorigenic effects 
depending on cellular context and concentration. The weight of evidence indicates 
that moderately elevated levels of protein nitrosylation stimulate the development and 
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progression of cancers while excessive levels provoke the activation of enzyme 
signalling cascades such as the Ras/Erk/MAP kinase pathway leading to cellular 
apoptosis 103. 
Stress as a modulator of immune response in depression and cancer 
Psychosocial stressors including low perceived social support, lack of familiar ties as 
well as history of childhood trauma and adverse life experiences appear to increase 
the susceptibility to chronic diseases, including MDD and cancer 104. Moreover, 
chronic psychosocial stress increases cancer mortality across a diverse array of cancer 
types (e.g., breast, lung, head and neck, hepatobiliary, lymphoid, and hematopoietic 
cancers) 105, 106. A possible behavioral explanation implies the fact that psychological 
stress exerts detrimental effects on sleep architecture integrity and increases fatigue. 
In addition, increased threat perception may promote unhealthy lifestyle choices 
including dietary habits, smoking and alcohol abuse, and lack of physical activity. 
Furthermore, stressors may be responsible for cognitive complaints, especially in the 
domain of memory, which could have a role in diminishing treatment compliance 107.  
However, at a mechanistic level, mounting evidence indicates that chronic stress 
confer increased vulnerability to chronic diseases amplifying pro-inflammatory 
signals via an increased production of cytokines and other immune mediators, as well 
as via a decreased sensitivity to hormonal inhibitory control by the HPA axis, as well 
altered autonomic responses 108, 109. Moreover, a pro-inflammatory milieu promotes 
oxidative and nitrosative stress that may promote mitochondrial dysfunction and 
DNA damage 110. This view is supported by evidence indicating that stressful 
experiences increase immune responses even in healthy individuals. For instance, the 
exposure to the Trier Social Stress Test (TSST), a test including tasks of mental 
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arithmetic and public speaking, has been associated with activation of NF-κB in 
peripheral blood mononuclear cells 111. However, individuals with MDD with early 
life stress exhibit an exaggerated pro-inflammatory activation in comparison to 
healthy individuals to psychosocial stressors 112.  
In subjects with cancer, stress appears to influence every phase of tumor progression, 
from cancer initiation to angiogenesis promotion and metastatic spread 113. A large 
body of preclinical data indicates that stress promotes inflammatory dysregulation and 
affect immune response in cancer models of depressive-like behavior 22. These data 
were also confirmed in clinical settings. For instance, lower social support predicted 
greater VEGF gene expression and higher IL-6 levels in individuals with colon and 
ovarian cancer respectively, suggesting enhanced angiogenic potential 114, 115. 
Moreover, low subjective social support has been associated with elevated 
intratumoral levels of norepinephrine in patients with ovarian cancer, thus 
instantiating the role of beta-adrenergic signaling on tumor growth control 116. 
Similarly, stress-induced autonomic response via beta-adrenergic transmission is 
associated with increased invasive potential through increased expression in MMPs 34. 
Moreover, stress promotes tumor cells resistance to programmed cell death in the pro-
inflammatory tumor microenvironment 117. Lastly, beta-adrenergic effects induce the 
loss of phagocytic abilities by tumor-associated macrophages and promote the 
propagation of the inflammatory response 35.  
High levels of psychological distress and low social support predict not only impaired 
activity of the immune innate system, but worse immune cellular response as well. In 
individuals with stage II and III breast cancer before a surgery intervention, high 
stress levels as assessed with a self-reported questionnaire (i.e., Impact of Event 
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Scale) predicted subsequent reduced lysis potential by natural killer (NK) cells, as 
well as diminished response of NK cells to IFN gamma and decreased proliferative 
response of peripheral blood lymphocytes to a monoclonal antibody stimulating the 
T-cell receptor 118. A subsequent small follow-up study involving a subset of patients 
demonstrated that dysfunctional alterations in NK-cells activity in association with 
high levels of psychological stress may be long-lasting, although the relevance of 
stress-induced detrimental effects on cancer survival and recurrence is still unclear 119.  
At a molecular level, epigenetic mechanisms have been posited to underlie many of 
the associations between environmental stress exposure and dysfunctional endocrine 
and immune response through its long-lasting impact on gene expression. The most 
studied epigenetic modifications include changes in the methylation of cytosine-
guanine dinucleotides (CpGs), but include as well histone modifications, silencing of 
the extra copy of the X-chromosome in females, genomic imprinting and alterations 
in non-coding RNA 120. Life adversities may influence molecular pathways relevant 
to the HPA-axis signaling and immune activation, leading to long-lasting 
immunological and endocrine dysfunction, which confers increased vulnerability to 
the subsequent development of depression and inflammatory diseases 121.  
For instance, early life adversities have been associated with increased cytosine 
methylation in the exon 1F of the neuron-specific glucocorticoid receptor (NR3C1) 
promoter, which leads to reduced hippocampal NR3C1 gene expression 122. Lower 
glucocorticoid receptor (GR) activity is related to the hyper-activation of the HPA 
axis. In keeping with this, another study showed that male victims of suicide with 
history of childhood adversities exhibit increased methylation in the promoter of the 
NR3C1 gene as compared to male victims without history of adversity, thus 
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supporting the idea that stress-induced epigenetic control of the GR expression is 
relevant to the pathophysiology of MDD 123. 
Moreover, childhood trauma-dependent DNA demethylation in the FK-506 binding 
protein 5 (FKBP5) gene, which codes for a heath shock protein (HSP)-90 co-
chaperone, has been linked to increased risk of developing psychiatric disorders in 
adulthood 124. In fact, when FKBP5 binds HSP-90, the complex decreases GR affinity 
to cortisol and prevents GR translocation to the cell nucleus and the consequent 
promotion of target genes transcription. Thus, as a result of stress-induced increased 
demethylation, the subsequent up-regulation of FKBP5 contributes to reduced GR 
sensitivity 125. Another candidate that has been repeatedly investigated for early 
stress-induced epigenetic changes in depression is the BDNF gene. Increased 
methylation of the promoter in the BDNF gene has been associated with reduced gene 
transcription and associated to increased suicidality among individuals with MDD 126. 
However, preliminary evidence indicates that changes in the methylation of the 
promoter of BDNF gene may occur only during the transition from adolescence to 
adulthood, suggesting the complexity of gene versus environment interactions in 
shaping developmental trajectories 127.  
Stress, gut dysbiosis, and the “leaky gut” 
During the first weeks of life, the gut is progressively colonized by a variety of 
symbionts, which are important for digestion and a relevant source of nutrients. The 
most common bacterial phyla present in the gut include the Firmicutes, Bacteroidetes, 
Actinobacteria, and Proteobacteria 128. The composition of microbiota is highly 
sensitive to the impact of chronic stress 129. A growing body of evidence indicates that 
the development of the CNS and of the HPA axis is highly influenced by alterations 
  
 23
in microbiota composition. For example, early stress in the perinatal period, including 
maternal separation, exerts a huge impact on the microbiota translating into long-
lasting immunological aberrations 130. Immune challenges in mice during pregnancy, 
induced with the administration of lipopolysaccharide or with direct injection of IL-6, 
are associated with increased gut permeability and increased IL-6 expression in the 
colonic epithelium of the off springs 131. Preclinical studies demonstrated that the 
absence of microbiota in germ-free animals is associated with behavioral 
abnormalities, altered gene expression in several brain areas, as well as with an 
increased turnover of key neurotransmitters, which may persist into adulthood 132. 
Under chronic stressful conditions and also MDD, commensal bacteria and microbial-
associated molecular patterns in the gut can leak into the peripheral circulation and 
activate the inflammasome, a cytosolic protein complex that lead to the amplification 
of pro-inflammatory responses via increased production of cytokines and other 
immune mediators 133, 134. Thus, major depression is accompanied by increased 
bacterial translocation of gram negative bacteria, such as Hafnia alvei, Pseudomonas 
aeruginosa, Morganella morganii, Pseudomonas putida, Citrobacter koseri, and 
Klebsiella pneumonia as indicated by increased IgM and IgA responses to the LPS of 
these commensal gut bacteria 135, 136. Moreover, this increased bacterial translocation 
in depression is associated with increased inflammatory responses, but especially with 
activated O&NS pathways, including lipid peroxidation and hypernitrosylation, and 
autoimmune responses to oxidative and nitrosative specific neoepitopes 137. In 
addition, in another disease strongly comorbid with depression, i.e. chronic fatigue 
syndrome, highly significant correlations were found between increased bacterial 
translocation through increased gut permeability (leaky gut) and increased levels of 
pro-inflammatory cytokines and autoimmune responses directed against serotonin 136, 
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137
. 
Therefore, increased bacterial translocation of gram negative bacteria following leaky 
gut play an important role in the amplification of pro-inflammatory and O&NS 
signals and Toll-like receptor (TLR) activation and thus the maintenance of chronic 
activation of immune-inflammatory pathways 95.   
Several studies suggest that microbiota dysbiosis also plays a pivotal role also in 
cancer, influencing the dynamic control of gene expression and immunosurveillance 
138
. The production by the microbiota of several low-molecular weight bioactive 
substances, including folate, butyrate, biotin and acetate is involved in the regulation 
of DNA expression, replication and repair, while also enabling immune-tolerance 138. 
These dynamic processes may be critical during early stages of carcinogenesis, as 
well as in more advanced phases related to tumor progression. For instance, folate is a 
vitamin acting as a carbon-unit acceptor, involved in several metabolic pathways, 
including the biosynthesis of nucleotides and amino acids 139. Its availability largely 
influences DNA replication, repair and methylation. Butyrate is a short-chain fatty 
acid, mostly produced by the Firmicute bacteria phyla, that has been shown to play a 
role in tumorigenesis by promoting the expression of epigenetically silenced genes 
through the inhibition of histone deacetylase 140. In addition, it enhances the 
production of pro-angiogenic factors driving tumor progression 141. Biotin is a vitamin 
not constitutively produced by humans and supplied by intestinal microbiota. 
Biotinylation of histone proteins is an important epigenetic process resulting in gene 
repression and relevant to DNA repair processes 142. Butyrate and acetate, which are 
fermentation products from dietary fibers metabolized by gut microbiota exert anti-
inflammatory activity and regulate the infiltration of macrophages 143. Thus, 
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alterations in the microbiome induce pro-inflammatory responses that may contribute 
to tumor initiation and development 144. Moreover, gut microbiota is a major donor of 
acetyl groups in histone acetylation reactions, which is an epigenetic regulatory 
mechanism influencing gene expression at the chromatin level 145. Since oncogenes’ 
signaling during carcinogenesis may affect acetylation processes and thus chromatin 
remodeling, gut microbiota manipulations with dietary strategies in cancer studies 
may increase the armamentarium of available treatment options. Interestingly, the 
modulation of microbiota composition via dietary intervention has recently emerged 
as a promising strategy for the treatment of major mental disorders, including 
depression 146, 147. 
The impact of behavioral strategies on depression associated with cancer 
Effects of Psychological treatments on depression in patients with cancer 
Recent results support the hypothesis that a variety of psychological interventions 
may be effective in promoting resilience to stress and reinforcing social support, 
including standard cognitive behavioral therapy and mindfulness-based therapy, but 
also multimodal approaches including psychoeducational interventions, anticipatory 
guidance and measures of psychosocial support 148. As recently reviewed elsewhere 
extensively 1, the majority of RCTs were performed on subjects suffering from breast 
cancer, while literature exploring the impact of psychological treatments in other 
types of cancer is relatively scarce, albeit rapidly growing . However, despite the 
scarceness of confirmatory studies, there is a large evidence supporting a model in 
which behavioral interventions may promote biological effects, with a positive impact 
on the innate and cellular immune response and in the modulation of the HPA axis 
activity. For instance, psychological treatment was effective in increasing the host T 
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cell response as well as enhancing the cytotoxicity of NK cells 149, 150. Significant 
increases in the percentage of large granular lymphocytes and NK cytotoxic activity 
and a small decrease in the percentage of TH CD4+ cells were observed following a 
6-week psychiatric group intervention for patients with malignant melanoma, and 
correlated with improvements in the affective symptoms’ severity 151. Reductions in 
cortisol levels or normalization of diurnal cortisol patterns have also been reported 150, 
152
. The changes in immunological and endocrine responses associated with 
psychological interventions do not seem only to exert a beneficial impact on coping 
strategies, stress relieving, affective symptoms and on quality of life measures 153-155, 
but there is also some evidence of a long-lasting effect on survival. For instance, in a 
study with a 11-year follow-up of breast cancer patients, psychological treatment was 
effective in reducing the risk of recurrence (hazard ratio [HR]= 0.55; 95% CI 0.28-
0.93) and death from breast cancer (HR = 0.44; 95% CI 0.32-0.957) 156. In addition, 
among those patients exhibiting a recurrence, a decreased risk of death was reported 
in the intervention arm as compared to controls (HR = 0.41; 95% CI 0.20–0.83) 157. 
Therefore, enhancing positive psychological resources through dedicated programs 
can be considered an adjunctive useful strategy in developing intervention protocols 
for decreasing depressive symptoms, and may improve survival through the 
amelioration of shared pathways involved in both the pathophysiology of depression 
and cancer survival. 
 
 
The influence of diet on tumorigenesis and depression 
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The potential of some dietary strategies in influencing biological pathways relevant to 
carcinogenesis is well supported by epidemiological data instantiating that diet 
enriched with fruits and vegetables may confer protection from the development of 
cancer (e.g., colorectal cancer) 158. In contrast, a diet enriched with refined grains has 
been associated with higher risk of colorectal cancer 159, as well as with a lowered 
cancer survival 160. Conversely, the supplementation with omega-3-fatty acids with 
2 g/day of fish oil for the first 9 week of chemotherapy was effective in contributing 
to delaying tumor progression and increasing survival in subjects with colorectal 
cancer 161. At a mechanistic level, omega-3-fatty acids appear to trigger apoptosis of 
colon cancer cells through a mitochondrial pathway 162. Furthermore, some of these 
beneficial effects of omega-3 fatty acids may be mediated by alteration in the gut 
microbiota 163.  
 
Cruciferous vegetables such as cabbage, broccoli, kale, and cauliflower are rich 
sources of fiber, lutein, flavonoids, phytosterols, folic acid, sulfur-containing 
glucosinolates and vitamin C, each of which has been associated with reduced risk of 
various kinds of cancer 164. In contrast, high dietary consumption of fat and processed 
red meat is associated with increased risk of cancer, possibly via increased activity of 
N-nitroso compounds and heterocyclic aromatic amines 165. In fact, gut microbiota 
appears to be pivotal mediators in the production of nitrosative reactive species from 
red meat consumption. The production of DNA-damaging nitrosative and oxidative 
reactive species by gut commensals has been posited to further increase the risk of 
cancer 166. Diet composition appears to influence as well metabolic pathways under 
hormonal control, for example in estrogen-driven breast, ovarian and endometrial 
cancers. The conversion of potentially genotoxic estrogens to their inactive 
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metabolites is mediated by hepatic conjugation via catechol-O-methyltransferase 
(COMT). The consumption of a diet enriched with vegetables (e.g., tomatoes), natural 
source of COMT, may thus exert a protective effect reducing the exposure to 
estrogens 167. 
 
Similarly, convergent data indicate that a diet enriched with the aforementioned 
elements may also exert a protective effect against the development of depressive 
symptoms. In fact, the most replicated clinical data informing on dietary 
recommendations for the prevention of depression indicates the benefits of increased 
consumption of fruit, vegetables, legumes, whole-grain cereals, nuts and seeds, fish 
rich in omega-3 polyunsaturated fatty acids as well as the limitation of the intake of 
processed-foods, 'fast' foods and commercial bakery goods 168. The following of 
traditional diets mainly composed with the above-mentioned healthy products, 
including the Mediterranean, Norwegian or Japanese diet, has been associated with 
decreased inflammation associated with cardiovascular disease and metabolic 
syndrome 169. In addition, the Mediterranean diet has been associated with 
improvements in depressive symptoms as well 170. Taken together these data indicate 
that behavioral interventions including dietary changes may serve as useful strategies 
to prevent the development of depressive symptoms. In addition, maladaptive dietetic 
and non-dietetic habits appear to modify the susceptibility to associated comorbidities 
and to worsen the prognostic outcome of cancer, thus representing a target for 
behavioral adjunctive treatment strategies. For instance, smoking has been associated 
with a high risk of recurrence in oropharynx cancer 171, as well as with lower 
adherence to treatments in breast cancer 172. Moreover, results of a recent meta-
analysis indicate that smoking increases the risk of recurrence of urothelial carcinoma 
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(HR=1.27, 95% C.I. = 1.09-1.46) and worsen prognostic outcome with decreased 
survival (HR=1.23, 95% C.I. = 1.02-1.44) 173. Schoenfeld and Ioannidis 174 selected 
50 ingredients from random recipes in a cookbook, and reviewed observational 
studies and meta-analyses performed for each ingredient. The authors found that 
although 40 (80%) ingredients had articles assessing their association with cancer 
risk, the epidemiological credibility of those associations was limited, and effect size 
estimates of relative risks (RR) from meta-analyses were on average null.  
The involvement of cancer patients in programs aiming at improving dietary 
education and promoting healthy lifestyle choices as a complementary treatment 
strategy may offer alternative opportunities to target both tumor progression and 
depressive symptoms. 
Physical activity 
Individuals with cancer are often affected by fatigue, which can also predate the 
clinical diagnosis and persist for several years. Fatigue significantly limits quality of 
life, reduces psychosocial functioning and is an independent predictor of decreased 
survival in individuals with terminal disease 175. Recent advances in the neurobiology 
of fatigue revealed that it is more likely to be related to biological pathways 
promoting neuroinflammation than with primary alterations involving the muscles 176. 
For instance, animal rat models of cancer-induced fatigue suggested that behavioral 
alterations occur in parallel with the increased expression of IL-1β mRNA in the 
cortex and the hippocampus 176.  
Exercise plays a vital role in improving physical fitness in cancer survivors 177. 
Moreover, physical activity should be considered as a key factor of lifestyle 
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interventions also to reverse negative treatment-related side effects 178. Since physical 
exercise has been recognized as a powerful modulator of neuroplasticity and immune 
response with immunosurveillance-enhancing properties 179, recent investigations 
started to increasingly explore the potential of additional exercise programs to usual 
treatment in improving psychosocial functioning as well as fatigue, cognitive 
functioning and depressive symptoms in individuals with cancer 180, 181. For instance, 
a small RCT on individuals with colorectal cancer undergoing chemotherapy 
documented that an adjunctive 18-week supervised exercise program improved 
fatigue, as assessed by the Multidimensional Fatigue Inventory (MFI) and the Fatigue 
Quality List (FQL), as well as physical functioning as compared to usual treatment 
182
. Similarly, a 12-week exercise program, utilizing a combination of aerobic and 
resistance exercise, demonstrated improved measures of fatigue in patients with 
haematological cancers 183. Another RCT on patients with prostate cancer undergoing 
a 12-week exercise program, comprising two supervised gym session and one home-
based session per week, documented a beneficial impact on depressive symptoms as 
assessed by the 20-item Center for Epidemiological Studies Depression Inventory 
(Cohen’s d = -0.35; 95% CI, -0.71 to 0.02) 184. In keeping with this view, in another 
RCT on patients with lung cancer, an adjunctive 12-week exercise intervention, 
consisting in moderate-intensity walking for 40 min per day, 3 days per week, was 
feasible and effective in reducing depressive symptoms and anxiety as assessed by the 
Hospital Anxiety and Depression Scale (HADS) 185. Another RCT, examining the 
differential impact between a high-intensity and a low-moderate regimen of physical 
exercise in subjects with cancer, demonstrated that both regimens are effective in 
reducing measures of fatigue and physical functioning as compared to wait-list 
controls 186. Moreover, physical exercise programs improved measures of work 
  
 31
functioning. In keeping with this view, a program of low-to-moderate intensity 
exercise was effective in improving fatigue, quality of life and depression in women 
with ovarian cancer 187.  
Classical yoga programs combining warming, postures and breathing exercises with 
relaxation are currently studied for their potentially beneficial impact on depressive 
symptoms, pain perception and fatigue in women with breast cancer 188. Similarly, an 
additional yoga program to usual treatment (e.g., surgery followed by adjuvant 
radiotherapy or chemotherapy) provided significant improvements in depressive 
symptoms’ severity on the Beck's Depression Inventory as compared to supportive 
therapy in a RCT involving patients with stage II and III breast cancer 189. However, 
other RCTs did not confirm these data 190. For instance, a 8-week yoga exercise 
program with twice-per-week sessions was effective in reducing fatigue in patients 
with non-metastatic breast cancer undergoing adjuvant chemotherapy but did not 
reduce depressive symptoms 191. 
Preliminary data instantiate also the potential of exercise programs in reversing at 
least in part some pro-inflammatory alterations associated with specific treatments in 
patients with cancer. For instance, in a RCT examining the effect of physical exercise 
on fatigue and on the levels of inflammatory markers in patients with breast cancer 
following radiation therapy, a program of progressive resistance exercise was 
effective in counteracting the increase in IL-6 levels and IL 6/IL-1RA ratio associated 
with radiation therapy 192. The impact of physical exercise on fatigue was partially 
attributable to the reduction in the levels of inflammatory markers. Moreover, 
physical exercise interventions exert regulatory effects on the HPA axis activity, with 
important implications for stress resilience. For instance, a 6-month a combined 
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program including exercise and hypocaloric diet in women with breast cancer was 
effective in reducing depressive symptoms on the BDI-II, which was associated to a 
normalisation of HPA axis regulation, as indicated by an increase in morning salivary 
cortisol at the 6-month follow-up in the intervention group as compared to controls 
193
. 
There is robust evidence from the non-cancer literature that physical activity is 
effective for reducing depression, including those with MDD 194. A recent systematic 
review indicates that these beneficial effects may be partly mediated by a decrease in 
oxidative stress and (neuro) inflammation, although the evidence remains limited 195.  
Taken together, these data indicate that physical exercise is a useful complementary 
intervention with potential beneficial effects on psychological stress, depression and 
fatigue among people with cancer. Further trials with larger samples and longer 
follow-up periods are warranted to evaluate the effects of exercise intervention for 
people suffering from different malignancies. Furthermore, trials with overall survival 
as the primary outcome are needed to determine whether the suggested benefits will 
translate into a survival advantage.  
 
Sleep dysfunction as a target in cancer-related depression  
The prevalence of poor sleep quality is common among cancer populations, affecting 
up to 50% of cancer survivors and being 2-fold or 3-fold that of general community 
196
. Sleep dysfunction consists of delayed sleep latency, waking episodes after sleep 
onset and reduced quality of sleep 197. Notwithstanding sleep disorders are 
acknowledged as predisposing risk factors for cancer development, their prevalence 
appear to rise during the course of the disease 197. Separate studies have documented 
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that sleep dysfunction usually occurs throughout the disease trajectory and is highly 
associated with psychological distress, fatigue and depression 198. For instance, in 
patients with cervical cancer before and after adjuvant therapy, poor sleep quality, as 
assessed by the Pittsburgh Sleep Quality Index, was significantly associated with 
depression, as assessed by the HADS and fatigue, as assessed by the MFI 198. 
Moreover, in this study, cancer treatments, including chemotherapy and possibly 
glucocorticoids and antiemetics significantly contributed to sleep problems, playing a 
major role in worsening sleep quality. In keeping with this view, in women with 
breast cancer receiving adjuvant treatment with tamoxifen, the duration of the 
chemotherapy treatment was significantly associated with the progressive increment 
of the number of awakenings and sleep disturbances 199. 
Notwithstanding these data suggest that the incidence of sleep dysfunction contributes 
to the severity of depression and fatigue in cancer populations, the direction of 
causality is highly debated to date, since other data demonstrated that sleep 
dysfunction is a strong predictor of relapse in MDD and a less powerful predictor of 
incident MDD in community-based populations 200, 201. 
Sleep architecture exerts deep influences on the modulation of the immune system’s 
activity. Sleep dysfunction and sleep deprivation result in an activation of pro-
inflammatory response with increased blood levels of IL-6 202. Additionally, sleep 
loss is associated with the upregulation of leukocyte expression of pro-inflammatory 
cytokine genes and increased NF-kB activity 203. Additionally, sleep disturbances 
appear to be associated also with a disrupted cortisol rhythm. For instance, in women 
with breast cancer, sleep disturbances and feeling less rested in the morning predicted 
lower awakening cortisol and a slower cortisol decline, suggesting an association 
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between a dysregulation of the HPA axis and sleep dysfunction 204.  
Since sleep dysfunction is acknowledged as a remarkable criterion for the diagnosis 
of depression, a derivative consideration from the abovementioned data is that 
interventions specifically targeting sleep disturbance in cancer might have a 
remarkable role in reducing subsequent depressive morbidity. Multimodal approaches 
using sleep hygiene and education, stimulus control, sleep restriction and relaxation 
and cognitive-behavioral therapy emerged as the gold standard for non-pharmacologic 
treatment of sleep dysfunction 205. However, further research is needed to examine the 
bi-directional relationships between sleep dysfunction and depression occurrence 
across different cancer populations. Furthermore, more studies are warranted to 
explore the role of sleep dysfunction in triggering pro-inflammatory alterations and 
influencing resilience to stress, with possible detrimental consequences for cancer 
outcome.  
Concluding remarks 
Individual suffering from cancer are at high risk of experiencing major depressive 
episodes throughout the trajectory of the disease, although most risk appears within 
the first year of diagnosis. Recent advances in the understanding of the 
neurobiological underpinnings of depression indicate that high levels of psychosocial 
stress and low social support may significantly contribute to the development of 
depressive symptoms in cancer populations, not only by increasing the psychological 
distress but also influencing biological mechanisms relevant for the pathophysiology 
of depression. A lower resilience to stress may translate into chronic inflammation 
and altered hormonal and autonomic responses, which are acknowledged factors 
related to the development and recurrences of depressive episodes. Likewise, stress 
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and depression through shared mechanisms may exert a detrimental effect on cancer-
related outcomes. Figure 1 provides a wide-angle lens of the multiple intertwined 
biobehavioral pathways linking stress, depression, and cancer progression.  Since 
antidepressants might insufficiently target depression in cancer populations, the 
development of alternative or complementary treatment strategies is highly warranted. 
Behavioral interventions may be feasible adjunctive strategies for targeting depressive 
symptoms, cognitive dysfunction, fatigue and sleep disturbances among individuals 
with cancer 206. 
<Insert Figure 1 around here> 
Notwithstanding, the literature in the field is typically limited by a small number of 
studies and heterogeneous inclusion criteria, short follow-up periods and 
heterogeneous assessment tools, which complicates the generalizability of results and 
complicates the comparison between studies, preliminary data from RCTs offered 
encouraging results. In addition, available literature suggests that the positive impact 
of behavioural strategies may be partially mediated by their anti-inflammatory 
potential in association with immunosurveillance-enhancing properties as well as with 
a modulatory impact on the activity in the HPA axis. 
Prospective research may provide clearer causal inferences about the mutual 
interactions between cancer and depression, and inform about novel possible 
therapeutic options. In addition, a more profound knowledge base in this emerging 
field could also offer novel perspectives for the design of preventative strategies for 
tackling depression in cancer survivors. 
FIGURE LEGEND 
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Fig. 1. Chronic stress may activate several intertwined biobehavioral mechanisms 
relevant for the development of depressive symptoms with a detrimental impact on 
cancer progression. 
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